Johnson & Johnson vs Eli Lilly stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
Johnson & Johnson is cheaper for its profits and has less debt. Eli Lilly is more profitable and grows faster.
Side by side
| Johnson & Johnson | Eli Lilly | |
|---|---|---|
| $651 billion | $1.20 trillion | |
| 28.5% | 31.7% | |
| +2.7% | +21.6% | |
| 24.3× | 58.1× | |
| 0.7 years | 1.1 years | |
| 21.0% | 34.8% | |
| 2.3% | 0.6% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: Johnson & Johnson vs McKesson · Johnson & Johnson vs Medtronic · Johnson & Johnson vs Merck & · Johnson & Johnson vs Merck KGaA · Eli Lilly vs McKesson · Eli Lilly vs Medtronic · Eli Lilly vs Merck & · Eli Lilly vs Merck KGaA

